MedTrace Logo

SNAPS Breast Cancer Patient Study Breast Cancer Patients

NCT05370300 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2024-03-06

No results posted yet for this study

Summary

Differential immunogenomic signatures from peripheral blood CD14 (phagocytic) and CD2 (non-phagocytic) cells have been associated with multiple cancers and disease states. In particular several large clinical studies at Immunis.AI have demonstrated robust immunogenomic signatures in early-stage prostate cancer. Immunis.AI therefore hypothesizes that a peripheral blood immunogenomic signature will identify patients with various stages of breast cancer from healthy negative controls.

Conditions

Interventions

DIAGNOSTIC_TEST

Blood test

Proprietary immunogenomic signature from peripheral blood CD14 and CD2 cells.

Sponsors & Collaborators

Principal Investigators

  • Kirk Wojno, MD · Immunis.AI

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-01
Primary Completion
2026-09-30
Completion
2027-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05370300 on ClinicalTrials.gov